Goto F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y (2000) Cilostazol stroke prevention study: A placebo controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9:147–157. https://doi.org/10.1053/jscd.2000.7216

Article  Google Scholar 

Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C, CSPS 2 group (2010) Cilostazol for prevention of secondary stroke (CSPS2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9:959–968. https://doi.org/10.1016/S1474-4422(10)70198-8

Article  CAS  PubMed  Google Scholar 

Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, Hoshino H, Sakai N, Okada Y, Tanaka K, Origasa H, Naritomi H, Houkin K, Yamaguchi K, Isobe M, Minematsu K, on behalf of the CSPS.com Trial Investigators (2019) Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol 18:539–548. https://doi.org/10.1016/S1474-4422(19)30148-6

Article  Google Scholar 

Liu Y, Shakur Y, Yoshitake M, Kambayashi J (2001) Cilostazol (Pletal®): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 19:369–386. https://doi.org/10.1111/j.1527-3466.2001.tb00076.x

Article  CAS  PubMed  Google Scholar 

Inoue T, Sohma R, Morooka S (1999) Cilostazol inhibits the expression of activation-dependent membrane surface glycoprotein on the surface of platelets stimulated in vitro. Thromb Res 93:137–143. https://doi.org/10.1016/S0049-3848(98)00172-8

Article  CAS  PubMed  Google Scholar 

Kariyazono H, Nakamura K, Shinkawa T, Yamaguchi T, Sakata R, Yamada K (2001) Inhibition of platelet aggregation and the release of p-selectin from platelets by cilostazol. Thromb Res 101:445–453. https://doi.org/10.1016/S0049-3848(00)00415-1

Article  CAS  PubMed  Google Scholar 

Yamamoto H, Takahashi K, Watanabe H, Yoshikawa Y, Shirakawa R, Higashi T, Kawato M, Ikeda T, Tabuchi A, Morimoto T, Kita T, Horiuchi H (2008) Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation. Circ J 72:1844–1851. https://doi.org/10.1253/circj.CJ-08-0289

Article  CAS  PubMed  Google Scholar 

Satoh K, Fukasawa I, Kanemaru K, Yoda S, Kimura Y, Inoue O, Ohta M, Kinouchi H, Ozaki Y (2012) Platelet aggregometry in the presence of PGE1 provides a reliable method for cilostazol monitoring. Thromb Res 130:616–621. https://doi.org/10.1016/j.thromres.2012.05.030

Article  CAS  PubMed  Google Scholar 

Yamanouchi J, Hato T, Niiya T, Nakagawa K, Kumon Y, Fujiwara H, Yakushijin Y, Yasukawa M (2011) Vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay for platelet response to cilostazol. Platelets 22:135–142. https://doi.org/10.3109/09537104.2010.525976

Article  CAS  PubMed  Google Scholar 

Geiger J, Brich J, Hönig-Liedl P, Eigenthaler M, Schanzenbächer P, Herbert JM, Walter U (2007) Specific impairment of human platelet P2Y(AC)ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Vasc Biol 7:249–52. https://doi.org/10.1161/01.atv.19.8.2007

Lee BK, Lee SW, Park SW, Lee SW, Park DW, Kim YH, Lee CW, Hong MK, Kim JJ, Jang S, Chi HS, Park SJ (2007) Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and p-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol 100:610–614. https://doi.org/10.1016/j.amjcard.2007.03.070

Article  CAS  PubMed  Google Scholar 

Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, Suzuki Y, Box LC, Shoemaker SB, Zenni MM, Bass GLA (2008) A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 29:2202–2211. https://doi.org/10.1093/eurheartj/ehn287

Article  CAS  PubMed  Google Scholar 

Jeong YH, Lee SW, Choi BR, Kim IS, Seo MK, Kwak CH, Hwang JY, Park SW (2009) Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity. Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study. J Am Coll Cardiol 53:1101–1109. https://doi.org/10.1016/j.jacc.2008.12.025

Article  CAS  PubMed  Google Scholar 

Toyoda K, Uchiyama S, Hoshino H, Kimura K, Origasa H, Naritomi H, Minematsu K, Yamaguchi T, for the CSPS.com Study Investigators (2015) Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. Int J Stroke 10:253–258. https://doi.org/10.1111/ijs.12420

Article  Google Scholar 

Yamazaki M, Uchiyama S, Iwata M (2001) Measurement of platelet fibrinogen binding and p-selectin expression by flow cytometry in patients with cerebral infarction. Thromb Res 104:197–205. https://doi.org/10.1016/S0049-3848(01)00350-4

Article  CAS  PubMed  Google Scholar 

Yamazaki M, Ohnishi T, Hosokawa K, Yamaguchi K, Yoneyama T, Kawashima A, Okada Y, Kitagawa K, Uchiyama S (2016) Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy. J Thromb Haemost 14:1788–1797. https://doi.org/10.1111/jth.13391

Article  CAS  PubMed  Google Scholar 

Fisher RG, Teitel ER, Yee AT, Chuang AZ (2013) Evaluation of the effectiveness of the AggreGuide A-100 in measuring platelet aggregation in individuals taking a high or low dose of aspirin. Lab Medicine 44:e83–e91. https://doi.org/10.1309/LMJF9WK85YAAAEYV

Article  Google Scholar 

Madhavi R, Rajasekhar D, Vanajakshamma V, Reddy GO, Kapil C, Sowjenya G (2018) Variability in antiplatelet drugs’ response in Indian patients undergoing percutaneous coronary intervention and outcome modification by tailored antiplatelet therapy. J Cardiol Cardiovasc Ther 9:555762. https://doi.org/10.19080/JOCCT.2018.09.555762

Hosokawa K, Ohnishi T, Fukasawa M, Kondo T, Sameshima H, Koide T, Tanaka K, Maruyama I (2012) A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc Res 83:154–161. https://doi.org/10.1016/j.mvr.2011.11.007

Article  PubMed  Google Scholar 

Hosokawa K, Ohnishi T, Sameshima H, Miura N, Ito T, Koide T, Maruyama I (2013) Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb Haemost 109:102–111. https://doi.org/10.1160/TH12-06-0441

Article  CAS  PubMed  Google Scholar 

Maruyama H, Takeda H, Dembo T, Nagoya H, Kato Y, Fukuoka T, Deguchi I, Horiuchi Y, Tanahashi N (2011) Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic atroke or carotid artery stenting using the VerifyNow P2Y12 assay. Intern Med 50:695–698. https://doi.org/10.2169/internalmedicine.50.4623

Article  CAS  PubMed  Google Scholar 

KhannaV HA, Mikael R, Sambu N, Englyst N, Curzen N (2014) Does the VerifyNow P2Y12 assay overestimate “therapeutic response” to clopidogrel? Insights using short thrombelastography Thromb Haemost 111:1150–1159. https://doi.org/10.1160/TH13-10-0856

Article  CAS  Google Scholar 

Bieber M, Schuhmann MK, Volz J, Kumar GJ, Vaidya JR, Nieswandt B, Pham M, Stoll G, Kleinschnitz C, Kraft P (2019) Description of a novel phosphodiesterase (PDE)-3 Inhibitor protecting mice from ischemic stroke independent from platelet function. Stroke 50:478–486. https://doi.org/10.1161/STROKEAHA.118

Article  CAS  PubMed  Google Scholar